Phase 2 Study of NOV-002 in Low and Intermediate-1 Risk Myelodysplastic Syndrome.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2014
At a glance
- Drugs Glutathione/cisplatin (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 12 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
- 23 Feb 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 26 Aug 2009 New trial record